Skip Navigation Bar
National Library of Medicine Technical BulletinNational Library of Medicine Technical Bulletin

Table of Contents: 2022 MARCH–APRIL No. 445

Previous Next

RxNorm March 2022 Release

RxNorm March 2022 Release. NLM Tech Bull. 2022 Mar-Apr;(445):b6.

2022 March 08 [posted]

The RxNorm March 2022 monthly release became available for download on Monday, March 7, 2022 and includes COMIRNATY, the brand name product for the Pfizer-BioNTech COVID-19 vaccine.

RxNorm Data Changes

Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY) Added

The Pfizer-BioNTech COVID-19 vaccine received U.S. Food and Drug Administration (FDA) approval on August 23, 2021, for individuals ages 16 years and older. Once vaccines are approved by the FDA, companies can market the vaccines under brand names. COMIRNATY is the brand name for the Pfizer-BioNTech COVID-19 vaccine.

The FDA-authorized Pfizer-BioNTech COVID-19 vaccine for individuals ages 16 years and older will be marketed as COMIRNATY towards the end of March 2022. No change was made to the vaccine's formula with the name change. Pfizer-BioNTech COVID-19 vaccine (also known as COMIRNATY) overview and safety information is available from the U.S. Centers for Disease Control and Prevention.

Here is the new COVID-19 related product concept in RxNorm:

2593847 SBD SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension [Comirnaty]
NLM Technical Bulletin National Library of Medicine National Institutes of Health